MedElevator Войти в исследования
← Поиск публикаций

DOI 10.7326/m23-2593

Медицинская библиотека · Annals of internal medicine · 2024

A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2.

Paules Catharine I, Wang Jing, Tomashek Kay M, Bonnett Tyler, Singh Kanal, Marconi Vincent C, Davey Richard T, Lye David C, Dodd Lori E, Yang Otto O, Benson Constance A, Deye Gregory A, Doernberg Sarah B, Hynes Noreen A, Grossberg Robert, Wolfe Cameron R, Nayak Seema U, Short William R, Voell Jocelyn, Potter Gail E, Rapaka Rekha R

Рандомизированное исследованиеСтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

BACKGROUND

The ACTT risk profile, which was developed from ACTT-1 (Adaptive COVID-19 Treatment Trial-1), demonstrated that hospitalized patients with COVID-19 in the high-risk quartile (characterized by low absolute lymphocyte count [ALC], high absolute neutrophil count [ANC], and low platelet count at baseline) benefited most from treatment with the antiviral remdesivir. It is unknown which patient characteristics are associated with benefit from treatment with the immunomodulator baricitinib.

OBJECTIVE

To apply the ACTT risk profile to the ACTT-2 cohort to investigate potential baricitinib-related treatment effects by risk quartile.

DESIGN

Post hoc analysis of ACTT-2, a randomized, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT04401579).

SETTING

Sixty-seven trial sites in 8 countries.

PARTICIPANTS

Adults hospitalized with COVID-19 (n = 999; 85% U.S. participants).

INTERVENTION: Baricitinib+remdesivir versus placebo+remdesivir.

MEASUREMENTS: Mortality, progression to invasive mechanical ventilation (IMV) or death, and recovery, all within 28 days; ALC, ANC, and platelet count trajectories.

RESULTS

In the high-risk quartile, baricitinib+remdesivir was associated with reduced risk for death (hazard ratio [HR], 0.38 [95% CI, 0.16 to 0.86]; P = 0.020), decreased progression to IMV or death (HR, 0.57 [CI, 0.35 to 0.93]; P = 0.024), and improved recovery rate (HR, 1.53 [CI, 1.16 to 2.02]; P = 0.002) compared with placebo+remdesivir. After 5 days, participants receiving baricitinib+remdesivir had significantly larger increases in ALC and significantly larger decreases in ANC compared with control participants, with the largest effects observed in the high-risk quartile.

LIMITATION: Secondary analysis of data collected before circulation of current SARS-CoV-2 variants.

CONCLUSION

The ACTT risk profile identifies a subgroup of hospitalized patients who benefit most from baricitinib treatment and captures a patient phenotype of treatment response to an immunomodulator and an antiviral. Changes in ALC and ANC trajectory suggest a mechanism whereby an immunomodulator limits severe COVID-19.

PRIMARY FUNDING SOURCE: National Institute of Allergy and Infectious Diseases.

Для цитирования: Paules Catharine I, Wang Jing, Tomashek Kay M, Bonnett Tyler, Singh Kanal, Marconi Vincent C, Davey Richard T, Lye David C, Dodd Lori E, Yang Otto O, Benson Constance A, Deye Gregory A, Doernberg Sarah B, Hynes Noreen A, Grossberg Robert, Wolfe Cameron R, Nayak Seema U, Short William R, Voell Jocelyn, Potter Gail E, Rapaka Rekha R. A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2.. Annals of internal medicine. 2024. DOI: 10.7326/m23-2593.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.